Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · June 24, 2023

Long-Term Safety and Efficacy of Sublingual Asenapine Treatment for Schizophrenia

Neuropsychopharmacology Reports


Additional Info

Neuropsychopharmacology Reports
Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication
Neuropsychopharmacol Rep 2023 May 25;[EPub Ahead of Print], T Kinoshita, Y Takekita, S Hiraoka, F Tamura, Y Iwama

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading